Drug transporters of platinum-based anticancer agents and their clinical significance

Andrews, 1990, Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma, Cancer Commun., 2, 93, 10.3727/095535490820874641 Ardizzoni, 2007, Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, J. Natl. Cancer Inst., 99, 847, 10.1093/jnci/djk196 Blair, 2009, Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin, Clin. Cancer Res., 15, 4312, 10.1158/1078-0432.CCR-09-0311 Borst, 2008, How do real tumors become resistant to cisplatin?, Cell Cycle, 7, 1353, 10.4161/cc.7.10.5930 Brabec, 2005, Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs, Drug Resist. Updat., 8, 131, 10.1016/j.drup.2005.04.006 Briz, 2002, Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells, Mol. Pharmacol., 61, 853, 10.1124/mol.61.4.853 Buchdunger, 2000, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J. Pharmacol. Exp. Ther., 295, 139 Burger, 2004, Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib, Cell Cycle, 3, 1502, 10.4161/cc.3.12.1331 Burger, 2004, Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump, Blood, 104, 2940, 10.1182/blood-2004-04-1398 Burger, 2005, Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps, Cancer Biol. Ther., 4, 747, 10.4161/cbt.4.7.1826 Burger, 2010, Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2), Br. J. Pharmacol., 159, 898, 10.1111/j.1476-5381.2009.00569.x Burland, 1975, Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man, Br. J. Clin. Pharmacol., 2, 481, 10.1111/j.1365-2125.1975.tb00564.x Buss, 2009, Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin, Int. J. Clin. Pharmacol. Ther., 47, 51, 10.5414/CPP47051 Chen, 2009, Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function, Pharmacogenomics J., 9, 127, 10.1038/tpj.2008.19 Choi, 2006, Platinum transporters and drug resistance, Arch. Pharm. Res., 29, 1067, 10.1007/BF02969293 Choy, 2008, Current status and future prospects for satraplatin, an oral platinum analogue, Clin. Cancer Res., 14, 1633, 10.1158/1078-0432.CCR-07-2176 Ciarimboli, 2010, Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions, Am. J. Pathol., 176, 1169, 10.2353/ajpath.2010.090610 Ciarimboli, 2005, Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2, Am. J. Pathol., 167, 1477, 10.1016/S0002-9440(10)61234-5 Cole, 1994, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells, Cancer Res., 54, 5902 Coluccia, 2007, Trans-platinum complexes in cancer therapy, Anticancer Agents Med. Chem., 7, 111, 10.2174/187152007779314080 de Jonge, 2010, Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation, Eur. J. Cancer, 46, 3016, 10.1016/j.ejca.2010.07.015 Desoize, 2002, Particular aspects of platinum compounds used at present in cancer treatment, Crit. Rev. Oncol. Hematol., 42, 317, 10.1016/S1040-8428(01)00219-0 Dobson, 2008, Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?, Nat. Rev. Drug Discov., 7, 205, 10.1038/nrd2438 Dobson, 2009, Implications of the dominant role of transporters in drug uptake by cells, Curr. Top. Med. Chem., 9, 163, 10.2174/156802609787521616 Eckardt, 2009, Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer, J. Clin. Oncol., 27, 2046, 10.1200/JCO.2008.19.3235 Eechoute, K., Sparreboom, A., Burger, H., Franke, R.M., Verweij, J., Loos, W.J., Wiemer, E.A.C., Mathijssen, R.H.J., 2010. Drug transporters and imatinib treatment: Implications for clinical practice. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-10-2250. Filipski, 2008, Interaction of cisplatin with the human organic cation transporter 2, Clin. Cancer Res., 14, 3875, 10.1158/1078-0432.CCR-07-4793 Filipski, 2009, Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity, Clin. Pharmacol. Ther., 86, 396, 10.1038/clpt.2009.139 Franke, 2010, Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-d-glucosaminidase, Clin. Cancer Res., 16, 4198, 10.1158/1078-0432.CCR-10-0949 Fu, 2006, Clinical application of oxaliplatin in epithelial ovarian cancer, Int. J. Gynecol. Cancer, 16, 1717, 10.1111/j.1525-1438.2006.00654.x Fujita, 2006, Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants, J. Pharm. Sci., 95, 25, 10.1002/jps.20536 Gately, 1993, Cellular accumulation of the anticancer agent cisplatin: a review, Br. J. Cancer, 67, 1171, 10.1038/bjc.1993.221 Giaccone, 2000, Clinical perspectives on platinum resistance, Drugs, 59, 9, 10.2165/00003495-200059004-00002 Go, 1999, Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin, J. Clin. Oncol., 17, 409, 10.1200/JCO.1999.17.1.409 Hall, 2008, The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy, Annu. Rev. Pharmacol. Toxicol., 48, 495, 10.1146/annurev.pharmtox.48.080907.180426 Hamaguchi, 1993, Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines, Cancer Res., 53, 5225 He, 2009, Analysis and update of the human solute carrier (SLC) gene superfamily, Hum. Genomics, 3, 195, 10.1186/1479-7364-3-2-195 Helleman, 2006, Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter, Cancer Biol. Ther., 5, 943, 10.4161/cbt.5.8.2876 Howell, 2010, Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs, Mol. Pharmacol., 77, 887, 10.1124/mol.109.063172 Huang, 2004, Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance, Cancer Res., 64, 4294, 10.1158/0008-5472.CAN-03-3884 Huang, 2008, Genetic variations and gene expression of transporters in drug disposition and response, Expert. Opin. Drug Metab. Toxicol., 4, 237, 10.1517/17425255.4.3.237 Ishida, 2002, Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals, Proc. Natl. Acad. Sci. U.S.A., 99, 14298, 10.1073/pnas.162491399 Ishikawa, 1996, Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells, J. Biol. Chem., 271, 14981, 10.1074/jbc.271.25.14981 Ishikawa, 1994, GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation, J. Biol. Chem., 269, 29085, 10.1016/S0021-9258(19)62016-8 Johnson, 1998, Recent insights into platinum drug resistance in cancer, Drug Resist. Updat., 1, 243, 10.1016/S1368-7646(98)80005-8 Kelland, 2007, Broadening the clinical use of platinum drug-based chemotherapy with new analogues, Satraplatin and picoplatin, Expert. Opin. Investig. Drugs, 16, 1009, 10.1517/13543784.16.7.1009 Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat. Rev. Cancer, 7, 573, 10.1038/nrc2167 Kim, 2009, Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer, Lung Cancer, 65, 105, 10.1016/j.lungcan.2008.10.008 Kindla, 2009, In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions, Expert. Opin. Drug Metab. Toxicol., 5, 489, 10.1517/17425250902911463 Koepsell, 2004, The SLC22 drug transporter family, Pflugers Arch., 447, 666, 10.1007/s00424-003-1089-9 Koepsell, 2007, Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications, Pharm. Res., 24, 1227, 10.1007/s11095-007-9254-z Koepsell, 2003, Organic cation transporters, Rev. Physiol. Biochem. Pharmacol., 150, 36, 10.1007/s10254-003-0017-x Kollmannsberger, 2006, Recent advances in management of patients with platinum-refractory testicular germ cell tumors, Cancer, 106, 1217, 10.1002/cncr.21742 Korita, 2010, Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma, Oncol. Rep., 23, 965 Kuo, 2007, The roles of copper transporters in cisplatin resistance, Cancer Metastasis Rev., 26, 71, 10.1007/s10555-007-9045-3 Larson, 2009, The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs, Mol. Pharmacol., 75, 324, 10.1124/mol.108.052381 Lebwohl, 1998, Clinical development of platinum complexes in cancer therapy: an historical perspective and an update, Eur. J. Cancer, 34, 1522, 10.1016/S0959-8049(98)00224-X Liu, 2009, Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity, Cancer Chemother. Pharmacol., 64, 847, 10.1007/s00280-009-1017-6 Lovejoy, 2008, cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: uptake, structure, function, and prospects, Proc. Natl. Acad. Sci. U.S.A., 105, 8902, 10.1073/pnas.0803441105 Ludwig, 2004, Nephrotoxicity of platinum complexes is related to basolateral organic cation transport, Kidney Int., 66, 196, 10.1111/j.1523-1755.2004.00720.x Martinez-Balibrea, 2009, Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy, Int. J. Cancer, 124, 2905, 10.1002/ijc.24273 Masereeuw, 2010, Therapeutic implications of renal anionic drug transporters, Pharmacol. Ther., 126, 200, 10.1016/j.pharmthera.2010.02.007 McKeage, 2007, Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation, Drugs, 67, 859, 10.2165/00003495-200767060-00003 McWhinney, 2009, Platinum neurotoxicity pharmacogenetics, Mol. Cancer Ther., 8, 10, 10.1158/1535-7163.MCT-08-0840 Mishima, 2002, The cellular pharmacology of oxaliplatin resistance, Eur. J. Cancer, 38, 1405, 10.1016/S0959-8049(02)00096-5 Misset, 2000, Oxaliplatin clinical activity: a review, Crit. Rev. Oncol. Hematol., 35, 75, 10.1016/S1040-8428(00)00070-6 More, 2010, Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue, Mol. Cancer Ther., 9, 1058, 10.1158/1535-7163.MCT-09-1084 Moriyama, 2008, Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics, Xenobiotica, 38, 1107, 10.1080/00498250701883753 Nakamura, 2010, Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity, Biochem. Pharmacol., 80, 1762, 10.1016/j.bcp.2010.08.019 Nakayama, 2004, Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy, Clin. Cancer Res., 10, 2804, 10.1158/1078-0432.CCR-03-0454 Nakayama, 2001, Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines, Oncol. Rep., 8, 1285 Nelson, 1984, Mechanisms for the renal secretion of cisplatin, Cancer Treat. Rep., 68, 849 Nose, 2006, Structure of the Ctr1 copper trans’PORE’ter reveals novel architecture, Trends Biochem. Sci., 31, 604, 10.1016/j.tibs.2006.09.003 Ohishi, 2002, ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma, Clin. Cancer Res., 8, 3767 Omote, 2006, The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations, Trends Pharmacol. Sci., 27, 587, 10.1016/j.tips.2006.09.001 Otsuka, 2005, A human transporter protein that mediates the final excretion step for toxic organic cations, Proc. Natl. Acad. Sci. U.S.A., 102, 17923, 10.1073/pnas.0506483102 Pabla, 2009, The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity, Am. J. Physiol. Renal. Physiol., 296, F505, 10.1152/ajprenal.90545.2008 Pan, 1999, A transfected cell model for the renal toxin transporter, rOCT2, Toxicol. Sci., 47, 181, 10.1093/toxsci/47.2.181 Rabik, 2009, Role of copper transporters in resistance to platinating agents, Cancer Chemother. Pharmacol., 64, 133, 10.1007/s00280-008-0860-1 Raghavan, 2003, Testicular cancer: maintaining the high cure rate, Oncology (Williston Park), 17, 218 Raymond, 1998, Oxaliplatin: a review of preclinical and clinical studies, Ann. Oncol., 9, 1053, 10.1023/A:1008213732429 Raymond, 2002, Cellular and molecular pharmacology of oxaliplatin, Mol. Cancer Ther., 1, 227 Raynaud, 1997, cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice, Clin. Cancer Res., 3, 2063 Rixe, 1996, Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel, Biochem. Pharmacol., 52, 1855, 10.1016/S0006-2952(97)81490-6 Rybak, 2009, Cisplatin ototoxicity and protection: clinical and experimental studies, Tohoku J. Exp. Med., 219, 177, 10.1620/tjem.219.177 Safaei, 2006, Role of copper transporters in the uptake and efflux of platinum containing drugs, Cancer Lett., 234, 34, 10.1016/j.canlet.2005.07.046 Safaei, 2004, The role of copper transporters in the development of resistance to Pt drugs, J. Inorg. Biochem., 98, 1607, 10.1016/j.jinorgbio.2004.05.006 Safaei, 2005, Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs, Crit. Rev. Oncol. Hematol., 53, 13, 10.1016/j.critrevonc.2004.09.007 Safaei, 2005, Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells, Clin. Cancer Res., 11, 756, 10.1158/1078-0432.756.11.2 Safaei, 2005, Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells, Mol. Cancer Ther., 4, 1595, 10.1158/1535-7163.MCT-05-0102 Samimi, 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B, Mol. Pharmacol., 66, 25, 10.1124/mol.66.1.25 Samimi, 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients, Clin. Cancer Res., 9, 5853 Schilder, 1994, Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule, Cancer Res., 54, 709 Shah, 2009, New-generation platinum agents for solid tumors, Future Oncol., 5, 33, 10.2217/14796694.5.1.33 Shahzad, 2009, Novel strategies for reversing platinum resistance, Drug Resist. Updat., 12, 148, 10.1016/j.drup.2009.09.001 Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933 Song, 2004, Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells, Mol. Cancer Ther., 3, 1543, 10.1158/1535-7163.1543.3.12 Stathopoulos, 2010, Liposomal cisplatin: a new cisplatin formulation, Anticancer Drugs, 21, 732, 10.1097/CAD.0b013e32833d9adf Sternberg, 2009, Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial, J. Clin. Oncol., 27, 5431, 10.1200/JCO.2008.20.1228 Stordal, 2007, A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship, Cancer Treat. Rev., 33, 688, 10.1016/j.ctrv.2007.07.013 Suhre, 2005, Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2, Mol. Pharmacol., 67, 1067, 10.1124/mol.104.004713 Surowiak, 2006, ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome, Clin. Cancer Res., 12, 7149, 10.1158/1078-0432.CCR-06-0564 Suzuki, 2001, The MRP family and anticancer drug metabolism, Curr. Drug Metab., 2, 367, 10.2174/1389200013338289 Taniguchi, 1996, A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation, Cancer Res., 56, 4124 Tanihara, 2009, Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2, Biochem. Pharmacol., 78, 1263, 10.1016/j.bcp.2009.06.014 Terada, 2007, Gene expression and regulation of drug transporters in the intestine and kidney, Biochem. Pharmacol., 73, 440, 10.1016/j.bcp.2006.10.010 Terada, 2008, Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A), Biochem. Pharmacol., 75, 1689, 10.1016/j.bcp.2007.12.008 Tsuda, 2009, Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells, J. Pharmacol. Exp. Ther., 329, 185, 10.1124/jpet.108.147918 Vaisman, 1998, The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts, Cancer Res., 58, 3579 Van Meerten, 2007, First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study, Br. J. Cancer, 96, 1348, 10.1038/sj.bjc.6603750 Versantvoort, 1995, Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein, Br. J. Cancer, 72, 82, 10.1038/bjc.1995.281 Wang, 2010, X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adduct, Proc. Natl. Acad. Sci. U.S.A., 107, 9584, 10.1073/pnas.1002565107 Wang, 2008, Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia, Clin. Pharmacol. Ther., 83, 258, 10.1038/sj.clpt.6100268 Yao, 2007, Cisplatin nephrotoxicity: a review, Am. J. Med. Sci., 334, 115, 10.1097/MAJ.0b013e31812dfe1e Yoh, 2004, Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer, Clin. Cancer Res., 10, 1691, 10.1158/1078-0432.CCR-0937-3 Yokoo, 2008, Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer, Drug Metab. Dispos., 36, 2299, 10.1124/dmd.108.023168 Yokoo, 2007, Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity, Biochem. Pharmacol., 74, 477, 10.1016/j.bcp.2007.03.004 Yonezawa, 2005, Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat, Biochem. Pharmacol., 70, 1823, 10.1016/j.bcp.2005.09.020 Yonezawa, 2006, Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family), J. Pharmacol. Exp. Ther., 319, 879, 10.1124/jpet.106.110346 Zair, 2008, Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney, Pharmacogenomics, 9, 597, 10.2217/14622416.9.5.597 Zhang, 2010, Status of bi- and multi-nuclear platinum anticancer drug development, Anticancer Agents Med. Chem., 10, 272, 10.2174/187152010791162270 Zhang, 2009, Predicting drug–drug interactions: an FDA perspective, AAPS J., 11, 300, 10.1208/s12248-009-9106-3 Zhang, 2006, Organic cation transporters are determinants of oxaliplatin cytotoxicity, Cancer Res., 66, 8847, 10.1158/0008-5472.CAN-06-0769 Zhang, 2009, MATE1 has an external COOH terminus, consistent with a 13-helix topology, Am. J. Physiol. Renal. Physiol., 297, F263, 10.1152/ajprenal.00123.2009 Zhou, 2008, Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development, Curr. Med. Chem., 15, 1981, 10.2174/092986708785132870 Zisowsky, 2007, Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells, Biochem. Pharmacol., 73, 298, 10.1016/j.bcp.2006.10.003 Zolk, 2009, Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2), Naunyn Schmiedebergs Arch. Pharmacol., 379, 337, 10.1007/s00210-008-0369-5 Zwelling, 1979, Mechanism of action of cis-dichlorodiammineplatinum(II), Cancer Treat. Rep., 63, 1439